Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Induced pluripotent stem cells (iPS cells) are a promising source for a cell-based therapy to treat Parkinson's disease (PD), in which midbrain dopaminergic neurons progressively degenerate. However, long-term analysis of human iPS cell-derived dopaminergic neurons in primate PD models has never been performed to our knowledge. Here we show that human iPS cell-derived dopaminergic progenitor cells survived and functioned as midbrain dopaminergic neurons in a primate model of PD (Macaca fascicularis) treated with the neurotoxin MPTP. Score-based and video-recording analyses revealed an increase in spontaneous movement of the monkeys after transplantation. Histological studies showed that the mature dopaminergic neurons extended dense neurites into the host striatum; this effect was consistent regardless of whether the cells were derived from patients with PD or from healthy individuals. Cells sorted by the floor plate marker CORIN did not form any tumours in the brains for at least two years. Finally, magnetic resonance imaging and positron emission tomography were used to monitor the survival, expansion and function of the grafted cells as well as the immune response in the host brain. Thus, this preclinical study using a primate model indicates that human iPS cell-derived dopaminergic progenitors are clinically applicable for the treatment of patients with PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Morizane et al. and Kikuchi et al. both showed that an improvement of engraftment and reduced immune reaction were observed using MHC matching of iPSC-derived dopaminergic neurons in unlesioned non-human primates [98,99].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [99]
In the citing paper
“A comprehensive study of human iPSC-derived dopamine neuron progenitor cells expressing specific markers of the neural floor plate (CORIN+; FOXA2+; TUJ1+; PAX6−) and transplanted into a monkey model of Parkinson’s disease showed stronger evidence of behavioural benefits, of cellular integration of mature dopamine neurons within the putamen, and of extension of their dense neurites into the host st”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [82]
In the citing paper
“Most of the transplanted cells expressed FOXA2 and a third expressed tyrosine hydroxylase consistent with mature functional dopamine neurons.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [82]
Citations
Cites
Advances in functional and structural MR image analysis and implementation as FSL
Smith, S. M., Jenkinson, M., Woolrich, M. W., Beckmann, C. F., Behrens, T. E. J., Johansen-Berg, H., Bannister, P. R., De Luca, M., Drobnjak, I., Flitney, D. E., et al. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.07.051 · Cited by 13,630
Jenkinson, M., Bannister, P., Brady, M., & Smith, S. (2002) · NeuroImage · doi:10.1006/nimg.2002.1132 · Cited by 11,888
Fast robust automated brain extraction
Smith, S. M. (2002) · Human Brain Mapping · doi:10.1002/hbm.10062 · Cited by 10,496
Zhang, Y., Brady, M., & Smith, S. (2001) · IEEE Transactions on Medical Imaging · doi:10.1109/42.906424 · Cited by 6,982
A global optimisation method for robust affine registration of brain images
Jenkinson, M., & Smith, S. (2001) · Medical Image Analysis · doi:10.1016/s1361-8415(01)00036-6 · Cited by 6,872
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Kriks, S., Shim, J.-W., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A., et al. (2011) · Nature · doi:10.1038/nature10648 · Cited by 1,907
Patlak, C. S., & Blasberg, R. G. (1985) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1985.87 · Cited by 1,673
Cited by
Items 201–300 of 705
Direct reprogramming into interneurons: potential for brain repair
Pereira, M., Birtele, M., & Ottosson, D. R. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03193-3 · Cited by 28
Barker, R. A., Lao–Kaim, N. P., Guzman, N. V., Athauda, D. S., Bjartmarz, H., Björklund, A., Church, A., Cutting, E., Daft, D., Dayal, V., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02567-2 · Cited by 31
Self-citationZhou, W., Xia, S., Wang, C., Yang, Q., Verkhratsky, A., & Niu, J. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07893-6 · Cited by 31
Zhang, S. Q., Lin, K. L., Law, C. Y., Liu, B., Fu, X., Tse, W. S., Wong, S. S. M., Sze, S. C. W., & Yung, K. K. L. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0111-0 · Cited by 26
Ni, P., Noh, H., Shao, Z., Zhu, Q., Guan, Y., Park, J. J., Arif, F., Park, J. M., Abani, C. P., Beaudreault, C. P., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.04.002 · Cited by 25
Interspecies Organogenesis for Human Transplantation
Crane, A. T., Aravalli, R. N., Asakura, A., Grande, A. W., Krishna, V. D., Carlson, D. F., Cheeran, M. C. ‐., Danczyk, G., Dutton, J. R., Hackett, P. B., et al. (2019) · Cell Transplantation · doi:10.1177/0963689719845351 · Cited by 26
Neuronal Replacement as a Tool for Basal Ganglia Circuitry Repair: 40 Years in Perspective
Björklund, A., & Parmar, M. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00146 · Cited by 27
“…of mDA progenitors in vitro and their performance—survival, growth, and function—after transplantation in rodent and primate PD models matches very well that seen with authentic fetal mDA neurons (see e.g., Sundberg et al., 2013; Grealish et al., 2014; Chen et al., 2016; Kikuchi et al., 2017).”
BackgroundResultSelf-citationXia, K., Chen, H., Wang, J., Feng, X. G., Gao, Y., Wang, Y., Deng, R., Wu, C., Luo, P., Zhang, M., et al. (2020) · Theranostics · doi:10.7150/thno.46854 · Cited by 27
“Male cynomolgus monkeys (Macaca fascicularis) show characteristic age-associated physiological changes comparable to those of human males [46-48], which makes them an ideal animal model for translational research, such as developing appropriate testosterone supplementation paradigms and evaluating the potential of ste…”
BackgroundRecruitment of calbindin into nigral dopamine neurons protects against MPTP‐Induced parkinsonism
Inoue, K., Miyachi, S., Nishi, K., Okado, H., Nagai, Y., Minamimoto, T., Nambu, A., & Takada, M. (2018) · Movement Disorders · doi:10.1002/mds.107 · Cited by 29
Jefri, M., Bell, S., Peng, H., Hettige, N. C., Maussion, G., Soubannier, V., Wu, H., Silveira, H., Théroux, J., Moquin, L., et al. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0180 · Cited by 24
“A dual SMAD inhibition approach to create neuroectoderm with simultaneous sonic hedgehog exposure is the most robust approach to date,(19) with various tweaks to this including the addition of FGF8b(20) or a CORIN selection step.(21) Still, subtle changes in dose or time for some”
MethodPostmortem Studies of Fetal Grafts in Parkinson’s Disease: What Lessons Have We Learned?
Li, J., & Li, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.666675 · Cited by 28
Ikeo, S., Yamamoto, Y., Ikeda, K., Sone, N., Korogi, Y., Tomiyama, L., Matsumoto, H., Hirai, T., Hagiwara, M., & Gotoh, S. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121031 · Cited by 27
“Besides, there have been reports of the transplantation of hPSC-derived cells into various human organs for therapeutic purposes [16,17].”
BackgroundCurrent status and future directions of clinical applications using iPS cells—focus on Japan
Tsujimoto, H., & Osafune, K. (2021) · FEBS Journal · doi:10.1111/febs.16162 · Cited by 30
Unraveling the Bone–Brain Axis: A New Frontier in Parkinson’s Disease Research
Liu, T., Wu, H., Li, J., Zhu, C., & Wei, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312842 · Cited by 26
Pavan, C., Davidson, K. C., Payne, N. L., Frausin, S., Hunt, C. J., Moriarty, N., Rubio, M. Á. B., Elahi, Z., Quattrocchi, A. T., Abu-Bonsrah, K. D., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.03.008 · Cited by 28
Modeling Neuropsychiatric and Neurodegenerative Diseases With Induced Pluripotent Stem Cells
LaMarca, E. A., Powell, S. K., Akbarian, S., & Brennand, K. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00082 · Cited by 30
Cell-Biological Requirements for the Generation of Dentate Gyrus Granule Neurons
Hatami, M., Conrad, S., Naghsh, P., Álvarez-Bolado, G., & Skutella, T. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00402 · Cited by 29
“After that, the rate of granule cell production decreases significantly (about 90% less neurons are generated in rats and humans of medium age in comparison to young animals; Schlessinger et al., 1975; McDonald and Wojtowicz, 2005; Knoth et al., 2010; Kempermann, 2011; Lopez-Rojas and Kreutz, 2016).”
Wenker, S. D., & Pitossi, F. J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0077-4 · Cited by 26
Utilizing Xenogeneic Cells As a Therapeutic Agent for Treating Diseases
Huang, C., Yang, C., & Shyr, C. (2021) · Cell Transplantation · doi:10.1177/09636897211011995 · Cited by 29
Han, F., Liu, Y., Huang, J., Zhang, X., & Wei, C. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.738529 · Cited by 26
Nakamura, R., Nonaka, R., Oyama, G., Jo, T., Kamo, H., Nuermaimaiti, M., Akamatsu, W., Ishikawa, K., & Hattori, N. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1202027 · Cited by 27
“In 2018, Takahashi and colleagues initiated a clinical trial of cell transplantation therapy for patients with PD to investigate the safety and efficacy of iPSC-derived CORIN-positive mDA progenitors (Takahashi, 2020).”
MethodInfluentialRole of PIWI-like 4 in modulating neuronal differentiation from human embryonal carcinoma cells
Subhramanyam, C. S., Cao, Q., Wang, C., Heng, Z. S., Zhou, Z., & Hu, Q. (2020) · RNA Biology · doi:10.1080/15476286.2020.1757896 · Cited by 25
“In fact, the stem cell-derived dopaminergic neurons have undergone successful preclinical testing in PD and AD models [28,58,59].”
BackgroundKim, J., Jeon, J., Song, B., Lee, N., Ko, S., Cha, Y., Leblanc, P. R., Seo, H., & Kim, K. (2022) · Nature Protocols · doi:10.1038/s41596-021-00673-4 · Cited by 24
Cendelín, J., Buffo, A., Hirai, H., Magrassi, L., Mitoma, H., Sherrard, R. M., Vožeh, F., & Manto, M. U. (2019) · The Cerebellum · doi:10.1007/s12311-018-0999-1 · Cited by 24
“However, even grafted immature Purkinje cells or progenitors cannot penetrate the environment of the mature internal granular layer to innervate their target, the deep cerebellar nuclear neurons [62], in contrast to grafted ESCs in other CNS regions, which do extend their axons to their targets [69].”
BackgroundResultYamane, M., Takaoka, N., Obara, K., Shirai, K., Aki, R., Hamada, Y., Arakawa, N., Hoffman, R. M., & Amoh, Y. (2021) · Cells · doi:10.3390/cells10040864 · Cited by 25
Baldeschi, A. C., Pittaluga, E., Andreola, F., Rossi, S., Cozzolino, M., Nicotera, G., Sferrazza, G., Pierimarchi, P., & Serafino, A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00020 · Cited by 26
“, 2000), but recent works demonstrated that, in the developing brain, it is specifically expressed on DA progenitor cells located in the floor plate, and is used as marker useful to enrich dopaminergic progenitors in studies on regenerative medicine for PD treatment (Doi et al., 2014; Kikuchi et al., 2017).”
BackgroundSingle-Cell Profiling of Coding and Noncoding Genes in Human Dopamine Neuron Differentiation
Nilsson, F., Storm, P., Sozzi, E., Gil, D. H., Birtele, M., Sharma, Y., Parmar, M., & Fiorenzano, A. (2021) · Cells · doi:10.3390/cells10010137 · Cited by 26
Self-citationLi, K., Li, X., Shi, G., Lei, X., Huang, Y., Bai, L., & Qin, C. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00238-1 · Cited by 24
Current Status and Challenges of Stem Cell Treatment for Alzheimer’s Disease
Pacheco‐Herrero, M., Soto-Rojas, L. O., Reyes-Sabater, H., Garcés‐Ramírez, L., de la Cruz‐López, F., Villanueva‐Fierro, I., & Luna‐Muñoz, J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200863 · Cited by 23
Hiramatsu, S., Morizane, A., Kikuchi, T., Doi, D., Yoshida, K., & Takahashi, J. B. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212934 · Cited by 25
Self-citationYamamoto, T., Sato, Y., Yasuda, S., Shikamura, M., Tamura, T., Takenaka, C., Takasu, N., Nomura, M., Dohi, H., Takahashi, M., et al. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac014 · Cited by 22
Application Prospect of Induced Pluripotent Stem Cells in Organoids and Cell Therapy
Zhang, T., Qian, C., Song, M., Tang, Y., Zhou, Y., Dong, G., Shen, Q., Chen, W., Wang, A., Shen, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052680 · Cited by 27
Open Science Meets Stem Cells: A New Drug Discovery Approach for Neurodegenerative Disorders
Han, C., Chaineau, M., Chen, C. X. ‐., Beitel, L. K., & Durcan, T. M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00047 · Cited by 22
“Intriguingly, neural precursor cells differentiated from reprogrammed iPSCs were reported to migrate into various brain regions upon transplantation, to differentiate into glia and neurons, including dopaminergic neurons, and to improve behavior in both rodent and primate models of PD (Wernig et al., 2008; Kikuchi et…”
BackgroundPluripotent Stem Cell-Based Therapeutics for Muscular Dystrophies
Selvaraj, S., Kyba, M., & Perlingeiro, R. C. R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.07.004 · Cited by 26
“Importantly, planned/ongoing iPSC-based clinical trials for macular degeneration (UMIN000011929)VI [80], Parkinson’s disease (UMIN000033564)VII [81], spinal cord injury [82] and ischemic heart disease [83] will provide key lessons for the future PSC-based cell therapeutics.”
BackgroundDrummond, N. J., Dolt, K. S., Canham, M. A., Kilbride, P., Morris, G. J., & Kunath, T. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.578907 · Cited by 24
Neural induction: Historical views and application to pluripotent stem cells
Sasai, N., Kadoya, M., & Ong, A. L. C. (2021) · Development Growth & Differentiation · doi:10.1111/dgd.12703 · Cited by 23
The history and status of dopamine cell therapies for Parkinson's disease
Barker, R. A., Björklund, A., & Parmar, M. (2024) · BioEssays · doi:10.1002/bies.202400118 · Cited by 25
Self-citationAdult hippocampal neurogenesis: New avenues for treatment of brain disorders
Chen, L., Li, Z., Wang, W., Zhou, Y., Li, W., & Wang, Y. (2025) · Stem Cell Reports · doi:10.1016/j.stemcr.2025.102600 · Cited by 32
Sun, Y. W., Feng, L., Liang, L., Stacey, G. N., Wang, C., Wang, Y., & Hu, B. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0522 · Cited by 21
Progress of iPS cell-based transplantation therapy for retinal diseases
Akiba, R., Takahashi, M., Baba, T., & Mandai, M. (2023) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-022-00974-5 · Cited by 22
“This innovation has created dozens of seeds, leading to translational research for various diseases including spinal cord injury [2], ischemic cardiomyopathy [3], and Parkinson’s disease [4].”
BackgroundiPS cell therapy 2.0: Preparing for next‐generation regenerative medicine
Hui, K. K., & Yamanaka, S. (2024) · BioEssays · doi:10.1002/bies.202400072 · Cited by 24
“…preclinical studies have successfully demonstrated the desired therapeutic effects by injecting iPSC-derived cell suspensions into target sites, [122,123] low engraftment rates and potential off-target engraftment suggest that further optimization (e.g., injection vehicles and devices, etc.)…”
Differentiation and regulation of CD4+ T cell subsets in Parkinson’s disease
Sun, X., Gu, R., & Bai, J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05402-0 · Cited by 27
“Another study from non-human primates found that human iPSCs-derived DA neurons improved the spontaneous motor capacity of MPTP-induced monkey PD models ( Macaca fascicularis ) and showed ample neurite formation [391].”
BackgroundФилиппова, А., Bonini, F., Efremova, L. V., Locatelli, M., Preynat‐Seauve, O., Béduer, A., Krause, K., & Braschler, T. M. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120707 · Cited by 27
Cell-based regenerative and rejuvenation strategies for treating neurodegenerative diseases
Deng, S., Xie, H., & Xie, B. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04285-7 · Cited by 28
“PD In 2011 and 2017, pre-clinical studies established proof of concept for dopamine (DA) neurons derived from human ESCs (hESCs) and human induced PSCs (hiPSCs) [75, 76].”
Raudzus, F., Schöneborn, H., Neumann, S., Secret, E., Michel, A., Fresnais, J., Brylski, O., Ménager, C., Siaugue, J., & Heumann, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-80253-w · Cited by 20
Microinstrumentation for Brain Organoids
Patel, D., Shetty, S., Acha, C., Pantoja, I. E. M., Zhao, A., George, D., & Gracias, D. H. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302456 · Cited by 25
Kuse, Y., & Taniguchi, H. (2019) · Cell Transplantation · doi:10.1177/0963689719888459 · Cited by 22
Hadi, F., Akrami, H., Totonchi, M., Barzegar, A., Nabavi, S. M., & Shahpasand, K. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15257 · Cited by 25
Frederiksen, H. R. S., Doehn, U., Tveden‐Nyborg, P., & Freude, K. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.623717 · Cited by 24
“…neurons explaining why differentiation protocols using cell sorting, to obtain a more pure population (Dell’Anno et al., 2014; Hallett et al., 2015; Kikuchi et al., 2017) provides more efficient transplants compared to research without cell sorting (Kriks et al., 2011; Gonzalez et al., 2015;…”
BackgroundGlobal Trends of Stem Cell Precision Medicine Research (2018–2022): A Bibliometric Analysis
Liu, M., Yang, F., & Xu, Y. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.888956 · Cited by 23
“The iPSC was transplanted into animal models for treating Parkinson’s disease (21), Huntington’s disease (22), Duchenne muscular dystrophy (23), Fanconi anemia (24), and hemophilia A (25) in preclinical studies.”
MethodBrás, J., Henriques, D., Moreira, R., Santana, M. M., Silva-Pedrosa, R., Adão, D., Bráz, S., Álvaro, A. R., de Almeida, L. P., & Mendonça, L. S. (2022) · Scientific Reports · doi:10.1038/s41598-022-16369-y · Cited by 23
Narváez-Pérez, L. F., Paz‐Bermúdez, F. J., Ávalos‐Fuentes, J. A., Campos‐Romo, A., Florán, B., & Segovia, J. (2023) · Gene Therapy · doi:10.1038/s41434-023-00414-0 · Cited by 22
“These include transplants of neurons derived from induced pluripotent stem cells (iPSc cells) [12].”
BackgroundCell reprogramming therapy for Parkinson’s disease
Dong, W., Liu, S., Li, S., & Wang, Z. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.390965 · Cited by 22
“…2006) that a few transcription factors (TFs) can reprogram terminally differentiated cells into stem cells (induced pluripotent stem cells [iPSCs]) in vitro , these cells have been widely used in cell therapy research (Hallett et al., 2015; Kikuchi et al., 2017a, b; Schweitzer et al., 2020).”
BackgroundMethodPluripotent Stem Cells for Modelling and Cell Therapy of Parkinson’s Disease
Lebedeva, O. S., & Lagarkova, M. A. (2018) · Biochemistry (Moscow) · doi:10.1134/s0006297918090067 · Cited by 19
Drummer, C., Vogt, E.-J., Heistermann, M., Roshani, B., Becker, T., Mätz‐Rensing, K., Kues, W. A., Kügler, S., & Behr, R. (2021) · Cells · doi:10.3390/cells10030505 · Cited by 22
Gaggi, G., Credico, A. D., Izzicupo, P., Iannetti, G., Baldassarre, A. D., & Ghinassi, B. (2021) · Biomedicines · doi:10.3390/biomedicines9070754 · Cited by 22
Solana‐Manrique, C., Sánchez‐Pérez, A. M., Paricio, N., & Muñoz‐Descalzo, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020620 · Cited by 21
Current status and future prospects of patient-derived induced pluripotent stem cells
Wang, Z., Zheng, J., Pan, R., & Chen, Y. (2021) · Human Cell · doi:10.1007/s13577-021-00592-2 · Cited by 20
Cell Reprogramming for Regeneration and Repair of the Nervous System
Clark, I. H., Roman, A., Fellows, E., Radha, S., Var, S. R., Roushdy, Z., Borer, S. M., Johnson, S., Chen, O. M., Borgida, J. S. W., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102598 · Cited by 23
Generation of hypothalamic neural stem cell-like cells in vitro from human pluripotent stem cells
Miwata, T., Suga, H., Kawaguchi, Y., Sakakibara, M., Kano, M., Taga, S., Soen, M., Ozaki, H., Asano, T., Sasaki, H., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.02.006 · Cited by 20
“Therefore, trial transplantation of neural progenitor cells or neural stem cells has been applied in clinical practice (Kikuchi et al., 2017; Nori et al., 2011).”
BackgroundLocalized immunomodulation technologies to enable cellular and organoid transplantation
Nash, A., Lokhorst, N., & Omid Veiseh, A. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.05.008 · Cited by 20
Comini, G., Kelly, R. L., Jarrin, S., Patton, T., Narasimhan, K., Pandit, A. S., Drummond, N. J., Kunath, T., & Dowd, E. (2024) · Journal of Neural Engineering · doi:10.1088/1741-2552/ad33b2 · Cited by 20
“…dopaminergic neurons have to be transplanted in a progenitor state (because they die if lifted from cell culture and transplanted in an advanced state of differentiation), several studies have now shown that this leads to highly variable in vivo survival and maturation rates [4, 13, 16–31].”
BackgroundInfluentialStem cell therapy for Parkinson’s disease using non-human primate models
Chen, Z., & Niu, Y. (2019) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2019.053 · Cited by 18
“There are two ways to obtain human NSCs (hNSCs), i. e., directly from the brain (Abe et al., 2016) and differentiated from other cells, including stem (Kim et al., 2004) and somatic cells (Ai et al., 2016).”
BackgroundPons-Espinal, M., Blasco-Agell, L., & Consiglio, A. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03700-x · Cited by 18
Liu, G.-F., Liu, C., Guo, Y., Wang, Y., Sun, T., Xu, J., Yang, P., Ma, C., Guan, W., & Wang, C. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355820 · Cited by 18
“In terms of generating DA neurons, iPSCs are very similar to ESCs in that they respond to the same differentiation cues and generate mature cells with highly similar functional properties (Kikuchi et al., 2017).”
Bench to bedside: Current advances in regenerative medicine
Clarke, G., Harley, P., Hubber, E.-L., Manea, T., Manuelli, L., Read, E., & Watt, F. M. (2018) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2018.05.006 · Cited by 18
Zhang, S., Sun, P., Lin, K., Chan, F. H. L., Gao, Q., Lau, W. F., Roy, V. A. L., Zhang, H., Lai, K. W. C., Huang, Z., et al. (2019) · Advanced Science · doi:10.1002/advs.201901822 · Cited by 19
Cell reprogramming: methods, mechanisms and applications
Zhu, F., & Nie, G. (2025) · Cell Regeneration · doi:10.1186/s13619-025-00229-x · Cited by 28
“…therapies have been used to treat a spectrum of diseases, such as age-related macular degeneration (Mandai et al. 2017), neurodegenerative disease (Kikuchi et al. 2017; Song et al. 2020a; Doi et al. 2020; Tao et al. 2021; Hiller et al. 2022; Brot et al. 2022), liver disease (Choi et al. 2020;…”
Personalized Medicine in Parkinson’s Disease: New Options for Advanced Treatments
Mishima, T., Fujioka, S., Morishita, T., Inoue, T., & Tsuboi, Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070650 · Cited by 24
“Indeed, a primate study shows significant improvement two years after transplantation of human iPSCs into a primate PD model [77].”
BackgroundManzini, P., Peli, V., Rivera-Ordaz, A., Budelli, S., Barilani, M., & Lazzari, L. (2022) · Biotechnology Reports · doi:10.1016/j.btre.2022.e00708 · Cited by 17
Insights into Human-Induced Pluripotent Stem Cell-Derived Astrocytes in Neurodegenerative Disorders
Kumar, M., Nguyen, T. P. N., Milanese, M., & Bonanno, G. (2022) · Biomolecules · doi:10.3390/biom12030344 · Cited by 21
Dental applications of induced pluripotent stem cells and their derivatives
Gao, P., Liu, S., Wang, X., & Ikeya, M. (2022) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2022.03.002 · Cited by 18
Nishioka, K., Imai, Y., Yoshino, H., Li, Y., Funayama, M., & Hattori, N. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.764917 · Cited by 18
Storm, P., Zhang, Y., Nilsson, F., Fiorenzano, A., Krausse, N., Åkerblom, M., Davidsson, M., Yuan, J., Kirkeby, A., Björklund, T., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn3057 · Cited by 21
“Moreover, this analysis confirms previous transcriptional studies ( 6 , 33 , 42 ) and extends them by showing that the DA progenitors are also highly homogeneous in terms of chromatin profile and gene accessibility.”
Self-citationStem Cell Therapy for Parkinson’s Disease
Han, F., & Hu, B. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-4370-8_3 · Cited by 18
Regenerative Medicine: Could Parkinson's be the First Neurodegenerative Disease to be cured?
Díaz, M. L. (2019) · Future Science OA · doi:10.2144/fsoa-2019-0035 · Cited by 19
“[28] reported that the DOPAminergic cells survived for at least 2 years and formed connections with the monkey brain cells.”
BackgroundBringing Induced Pluripotent Stem Cell Technology to the Bedside
Karagiannis, P., Nakauchi, A., & Yamanaka, S. (2018) · JMA Journal · doi:10.31662/jmaj.2018-0005 · Cited by 20
Zygogianni, O., Antoniou, N., Kalomoiri, M., Kouroupi, G., Taoufik, E., & Matsas, R. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02781-w · Cited by 18
Izrael, M., Chebath, J., Molakandov, K., & Revel, M. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115525 · Cited by 18
Okyere, S. K., Zeng, C., Dong, Y., & Hu, Y. (2020) · Venoms and Toxins · doi:10.2174/2666121701999201104163407 · Cited by 21
Bhargava, A., Sandoval-Castellanos, A. M., Shah, S. S., & Ning, K. (2022) · Interface Focus · doi:10.1098/rsfs.2022.0040 · Cited by 15
Yeap, Y. J., Tng, T. J. W., Lee, M. J., Goh, M., & Lim, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032523 · Cited by 23
Culturing human pluripotent stem cells for regenerative medicine
Ozawa, H., Matsumoto, T., & Nakagawa, M. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2225701 · Cited by 20
“neurons [86], and CD200(-), ITGB4(+), and SSET4(+) selection”
BackgroundSelf-citationNuclear-cytoplasmic shuttling of class IIa histone deacetylases regulates somatic cell reprogramming
Luo, Z., Qing, X., Benda, C., Huang, Z., Zhang, M., Huang, Y., Zhang, H., Wang, L., Lai, Y., Ward, C., et al. (2019) · Cell Regeneration · doi:10.1016/j.cr.2018.11.001 · Cited by 17
ALS, a cellular whodunit on motor neuron degeneration
Karagiannis, P., & Inoue, H. (2020) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103524 · Cited by 17
Self-citationAdvanced Materials to Enhance Central Nervous System Tissue Modeling and Cell Therapy
Muckom, R. J., Sampayo, R. G., Johnson, H. J., & Schaffer, D. V. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202002931 · Cited by 17
Stem Cell Treatments for Parkinson’s Disease
Stoker, T. B. (2018) · Codon Publications eBooks · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch9 · Cited by 19
“iPSC-derived neural grafts have been trialed in primates with MPTP-induced nigral toxicity, with promising results (57).”
BackgroundLin, K., Liu, B., Lim, S.-L., Fu, X., Sze, S. C. W., Yung, K. K. L., & Zhang, S. (2019) · Journal of Ginseng Research · doi:10.1016/j.jgr.2019.03.001 · Cited by 16
“Because the main pathogenesis of neurodegenerative disease is neuron death or deactivation in the brain, a promising therapeutic strategy for the ultimately curing neurodegenerative diseases is neuron regeneration [2] by transplanting neurons differentiated from neural stem cells (NSCs) in vitro or, even better, promo…”
BackgroundMatsumura, H., Marushima, A., Ishikawa, H., Toyomura, J., Ohyama, A., Watanabe, M., Takaoka, S., Bukawa, H., Matsumura, A., Matsumaru, Y., et al. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10223-w · Cited by 15
Giovannini, D., Andreola, F., Spitalieri, P., Krasnowska, E. K., Baldeschi, A. C., Rossi, S., Sangiuolo, F. C., Cozzolino, M., & Serafino, A. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00723-6 · Cited by 17
Pluripotent stem cell strategies for rebuilding the human brain
Limone, F., Klim, J. R., & Mordes, D. A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1017299 · Cited by 18
Zhang, H., Yang, J., Guo, Y., Lü, P., Gong, X., Chen, K., Li, X., & Tang, M. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1359294 · Cited by 18
Goggi, J., Qiu, L., Liao, M.-C., Khanapur, S., Jiang, L., Ramasamy, B., Hartimath, S. V., Cheng, P. K. C., Yong, F., Soh, V., et al. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01868-4 · Cited by 15
Role of the Peripheral Nervous System in PD Pathology, Diagnosis, and Treatment
Ma, C., Zhang, W., & Cao, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.598457 · Cited by 15
Kimura, K., Koizumi, T., Urasawa, T., Ohta, Y., Takakura, D., & Kawasaki, N. (2021) · Scientific Reports · doi:10.1038/s41598-021-90102-z · Cited by 15
Kim, I.-K., Park, J., Kim, B., Hwang, K., & Song, B. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i9.1215 · Cited by 21
Yue, C., Feng, S., Chen, Y., & Jing, N. (2022) · Cell Regeneration · doi:10.1186/s13619-022-00128-5 · Cited by 17
Regenerative Therapies for Parkinson’s Disease: An Update
Stoker, T. B., & Barker, R. A. (2018) · BioDrugs · doi:10.1007/s40259-018-0294-1 · Cited by 15
Ueno, R., Takase, H., Suenaga, J., Kishimoto, M., Kurihara, Y., Takei, K., Kawahara, N., & Yamamoto, T. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113068 · Cited by 15
Restorative cell and gene therapies for Parkinson's disease
Barker, R. A., & Björklund, A. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00012-6 · Cited by 16
Metadata
- Authors
- Kikuchi, T., Morizane, A., Doi, D., Magotani, H., Onoe, H., Hayashi, T., Mizuma, H., Takara, S., Takahashi, R., Inoue, H., Morita, S., Yamamoto, M., Okita, K., Nakagawa, M., Parmar, M., & Takahashi, J.
- Affiliations
- Kyoto University (JP)
- RIKEN (JP)
- Lund University (SE)
- Corresponding author
- Takahashi, Jun
- ORCID
- Venue
- Nature
- Published
- 2017-08
- Volume
- 548
- Issue
- 7669
- Pages
- 592-596
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2751466955
- Cited by
- 702
- References
- 48
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 74 · 2023: 69 · 2022: 91 · 2021: 89 · 2020: 123 · 2019: 88 · 2018: 75 · 2017: 6
- FWCI
- 32.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (15H02502, 15H02540, 16H03306, 15K12779, 16H03300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, dopaminergic neurons, induced pluripotent stem cells, cell transplantation, nonhuman primate model, Macaca fascicularis, MPTP-induced neurotoxicity, midbrain dopaminergic neurons, spontaneous movement, neurite outgrowth, corin, tumor formation, cell survival, cell tracking, immune response, cell therapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Animals, Cell Survival, Disease Models, Animal, Humans, Macaca fascicularis, Magnetic Resonance Imaging, Male, Mesencephalon, Movement, Parkinson Disease, Serine Endopeptidases, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurites, Neostriatum, Regenerative Medicine, Cell Proliferation, Positron-Emission Tomography, Induced Pluripotent Stem Cells, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.